173 related articles for article (PubMed ID: 18558304)
41. Therapeutic strategies for secondary hyperparathyroidism in dialysis patients.
Ogata H; Koiwa F; Ito H; Kinugasa E
Ther Apher Dial; 2006 Aug; 10(4):355-63. PubMed ID: 16911189
[TBL] [Abstract][Full Text] [Related]
42. Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease.
Plosker GL
Pharmacoeconomics; 2011 Sep; 29(9):807-21. PubMed ID: 21838333
[TBL] [Abstract][Full Text] [Related]
43. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients.
Serra AL; Savoca R; Huber AR; Hepp U; Delsignore A; Hersberger M; Wüthrich RP
Nephrol Dial Transplant; 2007 Feb; 22(2):577-83. PubMed ID: 17005527
[TBL] [Abstract][Full Text] [Related]
44. Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroidism?
Kakuta T; Tanaka R; Kanai G; Sawaya A; Hirukawa T; Sato A; Saito A
Ther Apher Dial; 2009 Oct; 13 Suppl 1():S20-7. PubMed ID: 19765255
[TBL] [Abstract][Full Text] [Related]
45. Pharmacodynamic effects of cinacalcet after kidney transplantation: once- versus twice-daily dose.
Kamar N; Gennero I; Spataru L; Esposito L; Guitard J; Lavayssière L; Cointault O; Gandia P; Durand D; Rostaing L
Nephrol Dial Transplant; 2008 Nov; 23(11):3720-6. PubMed ID: 18558623
[TBL] [Abstract][Full Text] [Related]
46. Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients.
El-Shafey EM; Alsahow AE; Alsaran K; Sabry AA; Atia M
Ther Apher Dial; 2011 Dec; 15(6):547-55. PubMed ID: 22107691
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis.
Montenegro J; Cornago I; Gallardo I; García-Ledesma P; Hernando A; Martinez I; Muñoz RI; Romero MA
Nephrology (Carlton); 2012 Jan; 17(1):26-31. PubMed ID: 22022934
[TBL] [Abstract][Full Text] [Related]
48. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
49. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
Henley C; Colloton M; Cattley RC; Shatzen E; Towler DA; Lacey D; Martin D
Nephrol Dial Transplant; 2005 Jul; 20(7):1370-7. PubMed ID: 15855208
[TBL] [Abstract][Full Text] [Related]
50. Cinacalcet cost and utility in dialysis patients.
Cohen E; Uribarri J
Semin Dial; 2005; 18(4):353-4. PubMed ID: 16076364
[No Abstract] [Full Text] [Related]
51. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.
de Francisco AL
Expert Opin Pharmacother; 2008 Apr; 9(5):795-811. PubMed ID: 18345956
[TBL] [Abstract][Full Text] [Related]
52. Adherence to K/DOQI guidelines for calcium-based phosphate binders in clinical practice.
Shastri J; Tran A; Covit A; Pepe J; Sherman RA
J Ren Nutr; 2008 Jul; 18(4):370-4. PubMed ID: 18558302
[TBL] [Abstract][Full Text] [Related]
53. Cinacalcet-associated cardiogenic shock in a patient with cardiomyopathy.
Tilling L; Colin Forfar J
Clin Ther; 2007 Feb; 29(2):352-6. PubMed ID: 17472827
[TBL] [Abstract][Full Text] [Related]
54. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism.
Serra AL; Schwarz AA; Wick FH; Marti HP; Wüthrich RP
Nephrol Dial Transplant; 2005 Jul; 20(7):1315-9. PubMed ID: 15941845
[TBL] [Abstract][Full Text] [Related]
55. Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism.
Franceschini N; Joy MS; Kshirsagar A
Expert Opin Investig Drugs; 2003 Aug; 12(8):1413-21. PubMed ID: 12882626
[TBL] [Abstract][Full Text] [Related]
56. Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.
Chertow GM; Correa-Rotter R; Block GA; Drueke TB; Floege J; Goodman WG; Herzog CA; Kubo Y; London GM; Mahaffey KW; Mix TC; Moe SM; Wheeler DC; Parfrey PS
Nephrol Dial Transplant; 2012 Jul; 27(7):2872-9. PubMed ID: 22529163
[TBL] [Abstract][Full Text] [Related]
57. Fooling the parathyroid gland--will there be health benefits?
Curhan G
N Engl J Med; 2004 Apr; 350(15):1565-7. PubMed ID: 15071132
[No Abstract] [Full Text] [Related]
58. Cinacalcet for secondary hyperparathyroidism in hemodialysis recipients.
Owda AK; Alam MG; Kumar J
N Engl J Med; 2004 Jul; 351(2):188-9; author reply 188-9. PubMed ID: 15247361
[No Abstract] [Full Text] [Related]
59. First treatment for serious complications of kidney disease, parathyroid cancer.
FDA Consum; 2004; 38(3):6. PubMed ID: 15218832
[No Abstract] [Full Text] [Related]
60. Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols.
Chertow GM; Lu ZJ; Xu X; Knight TG; Goodman WG; Bushinsky DA; Block GA
Hemodial Int; 2012 Apr; 16(2):188-97. PubMed ID: 22118402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
